| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
Departments of 1 Pharmacology and Therapeutics, and 2 Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York
Requests for reprints: Adam R. Karpf, Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263. Phone: 716-845-8305; Fax: 716-845-8857; E-mail: adam.karpf{at}roswellpark.org.
DNA methyltransferase 1 (DNMT1)deficient mice are tumor-prone, and this has been proposed to result from the induction of genomic instability. To address whether loss of DNMT1, or the related protein DNMT3b, results in genomic instability in human cancer cells, we used a near-diploid human colorectal cancer cell line, HCT116, in which one or both DNMT genes were disrupted by homologous recombination. Array-based comparative genomic hybridization analyses indicated that double, but not single, DNMT knock-out cells display two specific alterations in regional DNA copy number, suggesting that DNMT deficiency and genomic DNA hypomethylation are not associated with widespread genomic amplifications or deletions in human cancer cells. However, spectral karyotype analyses revealed that DNMT-deficient HCT116 cells are highly unstable with respect to large-scale chromosomal alterations; furthermore, this effect is characterized by a high degree of individual cell heterogeneity. The induction of chromosomal alterations in DNMT-deficient cells was evidenced both by aneuploidy and by large increases in the number of novel chromosomal translocations. Studies of double knock-out cells indicated that the generation of chromosomal alterations is spontaneous and persistent in vitro, meeting the formal definition of genomic instability. In summary, we show that DNMT deficiency in human cancer cells results in constitutive genomic instability manifested by chromosomal translocations.
This article has been cited by other articles:
![]() |
S. R. Morey Kinney, D. J. Smiraglia, S. R. James, M. T. Moser, B. A. Foster, and A. R. Karpf Stage-Specific Alterations of DNA Methyltransferase Expression, DNA Hypermethylation, and DNA Hypomethylation during Prostate Cancer Progression in the Transgenic Adenocarcinoma of Mouse Prostate Model Mol. Cancer Res., August 1, 2008; 6(8): 1365 - 1374. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Ji, L. Yang, L. Yu, J. Yuan, D. Hu, W. Zhang, J. Yang, Y. Pang, W. Li, J. Lu, et al. Epigenetic silencing of O6-methylguanine DNA methyltransferase gene in NiS-transformed cells Carcinogenesis, June 1, 2008; 29(6): 1267 - 1275. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Esteller Epigenetics in Cancer N. Engl. J. Med., March 13, 2008; 358(11): 1148 - 1159. [Full Text] [PDF] |
||||
![]() |
J. Rodriguez, L. Vives, M. Jorda, C. Morales, M. Munoz, E. Vendrell, and M. A. Peinado Genome-wide tracking of unmethylated DNA Alu repeats in normal and cancer cells Nucleic Acids Res., February 11, 2008; 36(3): 770 - 784. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Palii, B. O. Van Emburgh, U. T. Sankpal, K. D. Brown, and K. D. Robertson DNA Methylation Inhibitor 5-Aza-2'-Deoxycytidine Induces Reversible Genome-Wide DNA Damage That Is Distinctly Influenced by DNA Methyltransferases 1 and 3B Mol. Cell. Biol., January 15, 2008; 28(2): 752 - 771. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Morey, D. J. Smiraglia, S. R. James, J. Yu, M. T. Moser, B. A. Foster, and A. R. Karpf DNA Methylation Pathway Alterations in an Autochthonous Murine Model of Prostate Cancer Cancer Res., December 15, 2006; 66(24): 11659 - 11667. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Rodriguez, J. Frigola, E. Vendrell, R.-A. Risques, M. F. Fraga, C. Morales, V. Moreno, M. Esteller, G. Capella, M. Ribas, et al. Chromosomal Instability Correlates with Genome-wide DNA Demethylation in Human Primary Colorectal Cancers. Cancer Res., September 1, 2006; 66(17): 8462 - 9468. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Cadieux, T.-T. Ching, S. R. VandenBerg, and J. F. Costello Genome-wide Hypomethylation in Human Glioblastomas Associated with Specific Copy Number Alteration, Methylenetetrahydrofolate Reductase Allele Status, and Increased Proliferation. Cancer Res., September 1, 2006; 66(17): 8469 - 8476. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |